This is part of FJN’s Topic Briefs for Journalists series.
View COVERING PSYCHEDELICS main page
PHOTO Pexels/Merlin
This section contains:
- Science of Psychedelics through the Ages
- Research Highlights
- Psychedelics in Therapeutic Settings
- Databases and Indexes of Ongoing Research
- Key Researchers and Contributors
Science of Psychedelics through the Ages
Rediscovery and scientific curiosity (1890–1960)
Psychedelics re-entered Western science at the turn of the 20th century. In 1897, Arthur Heffter isolated mescaline from peyote. Later, William James and Havelock Ellis experimented with it, documenting profound shifts in perception.
Then, in 1938, Albert Hofmann synthesized LSD while studying ergot alkaloids for pharmaceutical purposes. Five years later, he accidentally absorbed a small amount and experienced the world’s first acid trip—a mixture of wonder and confusion that changed psychiatry forever.
By the 1950s, psychedelics were hailed as revolutionary tools for psychology. Researchers like Stanislav Grof, Humphry Osmond, and Timothy Leary believed these substances could illuminate the unconscious mind. LSD therapy showed promise for alcoholism, depression, and trauma. More than 1,000 scientific papers and 40,000 subjects were studied in what many call the “first psychedelic renaissance.”
Cultural explosion and counterculture (1960–1970)
As psychedelics spread from laboratories to living rooms, the 1960s saw an unprecedented cultural upheaval. Figures like Timothy Leary, Ken Kesey, and The Beatles turned LSD into a symbol of freedom and rebellion. “Turn on, tune in, drop out,” became Leary’s mantra.
Psychedelics influenced music (The Doors, Jimi Hendrix, Pink Floyd), art (the psychedelic poster movement), and philosophy (Alan Watts, Aldous Huxley). They reshaped consciousness in certain segments of Western culture, challenging norms about war, conformity, and spirituality.
But misuse and political panic soon followed. Reports of psychotic episodes, reckless experimentation, and government anxiety led to prohibition. By 1970, the U.S. Controlled Substances Act classified LSD, psilocybin, and mescaline as Schedule I drugs—highly illegal with “no accepted medical use.”
The psychedelic age ended in stigma. Research funding vanished; scientists lost licenses. For decades, psychedelics retreated into underground therapy and indigenous rituals.
The long silence and the underground (1970–2000)
Despite prohibition, psychedelics never disappeared. Underground therapists continued to use MDMA (then still legal) in couples counseling and trauma therapy. Visionary communities preserved ayahuasca traditions. Writers and thinkers like Terence McKenna kept the conversation alive, emphasizing the connection between psychedelics, ecology, and human evolution.
Meanwhile, neuroscience quietly advanced. By the 1990s, researchers could map brain activity, setting the stage for a scientific reawakening.
The psychedelic renaissance (2000 – today)
The 21st century has witnessed a profound revival in psychedelic science. Pioneering institutions: Johns Hopkins University, Imperial College London, MAPS, and others have reopened the field with rigorous clinical protocols.
Modern research shows that psychedelics can:
- Reduce depression and anxiety (especially psilocybin-assisted therapy)
- Ease end-of-life distress in terminal patients
- Treat PTSD and addiction, particularly with MDMA and ibogaine
- Increase neural plasticity, encouraging new connections in the brain
- Induce lasting personality changes, such as openness and empathy
Brain imaging reveals that psychedelics quiet the default mode network, a system linked to self-referential thinking. When this “ego network” relaxes, people report mystical or unitive experiences—a sense of connection to all life.
This aligns with what shamans and mystics have said for ages: that healing often begins when the boundaries of the self dissolve.
Misuse and caution
Despite their promise, psychedelics are not risk-free. Unsuitable settings, improper doses, or psychological instability can lead to panic, confusion, or lasting trauma. In the 1960s, casual use led to accidents and cultural backlash. Even today, black-market substances may be adulterated or misused without guidance.
Responsible use emphasizes “set and setting”—a term coined in the early studies. The mindset of the user (set) and the environment (setting) profoundly shape the experience. Indigenous and clinical traditions alike agree: these substances are powerful tools, not toys.
The future of psychedelics
Psychedelics are once again moving from the fringes to the mainstream. In 2020, Oregon became the first U.S. state to legalize psilocybin therapy. Australia followed with MDMA- and psilocybin-assisted treatments for PTSD and depression. Major universities now run dedicated psychedelic research centers, and investors are pouring millions into biotech startups exploring novel compounds.
Yet, as society rediscovers these ancient medicines, an ethical question remains: how to integrate them wisely? Indigenous cultures have long understood that psychedelics are sacraments—meant to teach respect, not indulgence. Modern science, for all its precision, must remember that lesson.
Research Highlights
Systematic reviews / meta-analyses
- Insights on psychedelics: A systematic review of therapeutic effects – Comprehensive review of therapeutic outcomes, linking psychedelic-induced insight to clinical improvements across studies.
- Bibliometric analysis of clinical psychedelic research (1965–2021) – Scholarly survey quantifying growth in psychedelic clinical trials, substance focus (MDMA, LSD, psilocybin), and evolving therapeutic applications.
- Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine – Peer-reviewed synthesis of pharmacological targets, neurobiological mechanisms, and clinical outcomes in psychiatric contexts.
Mechanisms & Neuroscience
- Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models – Reviews how psychedelics potentiate neuroplasticity, with implications for therapeutic longevity and mechanism translation.
- Multimodal EEG-fMRI analysis under psilocybin (“Brain-MGF”) – Cutting-edge computational neuroscience work demonstrating brain network reconfiguration associated with psilocybin.
Historical and Conceptual Context
- Narrative review of the clinical evolution of psychedelic treatment – Traces pre-prohibition and modern clinical trial paradigms to inform current methodologies and interpretative frameworks. Nature
- The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry – Recent open-access review emphasizing mood disorder, PTSD, addiction treatment prospects, and the need for multidisciplinary study.
Benchmark clinical and translational studies
While specific clinical trial publications vary by substance and condition, key recurring themes include studies like these:
- Psilocybin-assisted therapy showing rapid antidepressant effects in treatment-resistant depression and reduction of existential distress in life-threatening illness.
- MDMA-assisted therapy demonstrating significant PTSD symptom reduction in phase 3 clinical contexts (reported in clinical news summaries).
- Converging evidence that psychedelic therapy, when paired with structured psychotherapeutic support, outperforms many conventional frameworks in chronic mood and substance use disorder contexts.
Psychedelics in therapeutic settings
- MDMA-assisted therapy for PTSD: Clinical trials sponsored by MAPS and published in Nature Medicine found that MDMA-assisted psychotherapy significantly reduced PTSD symptoms, with many participants no longer meeting diagnostic criteria after treatment. Researchers have discovered that MDMA reduces fear responses and increases emotional openness during trauma processing. (Live Science)
- Psilocybin for treatment-resistant depression: Researchers at Imperial College London Centre for Psychedelic Research and other institutions have shown that psilocybin can produce rapid antidepressant effects after only one or two guided sessions. Brain imaging studies indicate that psilocybin temporarily disrupts rigid neural patterns associated with depression. (Nature)
- Reduction of anxiety and existential distress in cancer patients: Studies associated with Johns Hopkins Center for Psychedelic and Consciousness Research found that psilocybin-assisted therapy reduced depression and end-of-life anxiety in patients with life-threatening illnesses, often producing long-lasting improvements in emotional well-being and acceptance of mortality. (arXiv)
- Psychedelics and neuroplasticity: Recent reviews by researchers including Robin Carhart-Harris and David Nutt suggest that psychedelics may enhance neuroplasticity — the brain’s ability to reorganize and form new neural connections. This mechanism may explain their lasting therapeutic effects in depression, PTSD, and addiction. (arXiv)
- Consciousness and mystical experience research: Scientists at Johns Hopkins Center for Psychedelic and Consciousness Research have investigated how psilocybin induces “mystical-type experiences” associated with increased meaning, spiritual well-being, openness, and psychological flexibility. These experiences are increasingly studied as part of consciousness research. (Nature)
- Real-world mental health improvements from psilocybin use: A large Johns Hopkins survey study reported that naturalistic psilocybin use was associated with persistent reductions in anxiety, depression, alcohol misuse, and burnout, alongside increases in emotional regulation and cognitive flexibility.
- Brain network and “ego dissolution” studies: Neuroimaging research funded by the National Institutes of Health (NIH) found that psychedelics such as psilocybin temporarily disrupt the brain’s default-mode network — a system associated with self-referential thinking. Researchers believe this may contribute both to therapeutic effects and to experiences of expanded or altered consciousness. (National Institutes of Health)
See COVERING PSYCHEDELICS: SOURCES for key researchers, journals, databases, and other resources.
Written by Jesper Madsen for FJN
